SV2006002069A - Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación - Google Patents
Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulaciónInfo
- Publication number
- SV2006002069A SV2006002069A SV2005002069A SV2005002069A SV2006002069A SV 2006002069 A SV2006002069 A SV 2006002069A SV 2005002069 A SV2005002069 A SV 2005002069A SV 2005002069 A SV2005002069 A SV 2005002069A SV 2006002069 A SV2006002069 A SV 2006002069A
- Authority
- SV
- El Salvador
- Prior art keywords
- rent
- halogen
- hydrogen
- independently hydrogen
- glucorregulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
PROPORCIONA METODOS PARA TRATAR LA ESQUIZOFRENIA Y/O ANOMALIAS DE GLUCORREGULACION EN UN PACIENTE QUE LO NECESITE, QUE COMPRENDE ADMINISTRAR A DICHO PACIENTE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA I: (VER FORMULA) EN LA QUE M ES 0,1 O 2; N ES 0,1 O 2; P ES 0 O 1; CADA R ES INDEPENDIENTEMENTE HIDROGENO, HALOGENO, TRIFLUOROMETILO, ALQUILO C1-C6, ALCOXI C1-C6, BENCILOXI, HIDROXI, NITRO O AMINO; CADA R1 ES INDEPENDIENTEMENTE HIDROGENO, ALQUILO C1-C6, ALQUENILO C1-C6, ALCANOILO C1-C6, HALOGENO, CIANO, -C(O)-ALQUILO (C1-C6), -ALQUILEN (C1-C6)-CN, -ALQUILEN (C1-C6)-NR´R´´ EN EL QUE R´ Y R´´ SON CADA UNO INDEPENDIENTEMENTE HIDROGENO O ALQUILO C1-C6, -ALQUILEN (C1-C6) -OC(O)-ALQUILO 8C1-C6), O -CH(OH)R4 EN EL QUE R4 ES HIDROGENO O ALQUILO C1-C6; R2 ES HIDROGENO, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI O BENCILOXI, ALQUENILO C1-C6, ALQUINILO C1-C6, -CO2-ALQUILO (C1-C6), O -R5-NR´R´´ EN EL QUE R5 INDEPENDIENTEMENTE HIDROGENO, ALQUILO C1-C6 O ALTERNATIVAMENTE EL GRUPO -NR´R´´ COMO UN SOLO GRUPO ES 1-PIRROLIDINILO; Y R3 ES HIDROGENO, NITRO, AMINO, HALOGENO, ALCOXI C1-C6, HIDROXI O ALQUILO C1-C6. O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2006002069A true SV2006002069A (es) | 2006-05-24 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2005002069A SV2006002069A (es) | 2004-04-01 | 2005-04-01 | Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (es) |
| EP (2) | EP2138176A1 (es) |
| JP (1) | JP2007531730A (es) |
| KR (1) | KR20070010161A (es) |
| CN (1) | CN1946399A (es) |
| AR (1) | AR048197A1 (es) |
| AT (1) | ATE446754T1 (es) |
| AU (1) | AU2005231446A1 (es) |
| BR (1) | BRPI0509512A (es) |
| CA (1) | CA2561162A1 (es) |
| CL (1) | CL2009001605A1 (es) |
| CY (1) | CY1109734T1 (es) |
| DE (1) | DE602005017373D1 (es) |
| DK (1) | DK1734959T3 (es) |
| DO (1) | DOP2005000050A (es) |
| ES (1) | ES2334241T3 (es) |
| GT (1) | GT200500063A (es) |
| IL (1) | IL178168A0 (es) |
| MX (1) | MXPA06011222A (es) |
| PA (1) | PA8628601A1 (es) |
| PL (1) | PL1734959T3 (es) |
| PT (1) | PT1734959E (es) |
| SI (1) | SI1734959T1 (es) |
| SV (1) | SV2006002069A (es) |
| TW (1) | TW200602040A (es) |
| WO (1) | WO2005097122A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| CL2007002950A1 (es) | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer |
| TW200825091A (en) * | 2006-10-12 | 2008-06-16 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds useful in treating sodium channel-mediated diseases or conditions |
| RU2011119626A (ru) | 2008-10-17 | 2012-11-27 | Ксенон Фармасьютикалз Инк. | Спирооксиндольные соединения и их применение в качестве терапевтичеких средств |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| EP2437744B1 (en) * | 2009-06-03 | 2015-06-03 | Marquette University | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| RU2015103694A (ru) | 2009-10-14 | 2015-06-27 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
| CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| CA3151507A1 (en) | 2016-08-24 | 2018-03-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| EP3941352A1 (en) * | 2019-03-19 | 2022-01-26 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| DE3852335T2 (de) * | 1987-04-24 | 1995-05-11 | Hoechst Roussel Pharma | N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel. |
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| EP0840609B1 (en) * | 1995-07-27 | 2002-06-05 | Aventis Pharmaceuticals Inc. | Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents |
| CZ220498A3 (cs) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
| DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| KR20010021936A (ko) | 1997-07-16 | 2001-03-15 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용 |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Application Discontinuation
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en active Application Filing
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es active Active
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de active Active
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Not-in-force
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1734959A2 (en) | 2006-12-27 |
| EP2138176A1 (en) | 2009-12-30 |
| WO2005097122A2 (en) | 2005-10-20 |
| CY1109734T1 (el) | 2014-09-10 |
| DOP2005000050A (es) | 2005-11-30 |
| KR20070010161A (ko) | 2007-01-22 |
| AR048197A1 (es) | 2006-04-05 |
| CA2561162A1 (en) | 2005-10-20 |
| PL1734959T3 (pl) | 2010-03-31 |
| MXPA06011222A (es) | 2007-01-16 |
| ATE446754T1 (de) | 2009-11-15 |
| WO2005097122A3 (en) | 2006-02-02 |
| SI1734959T1 (sl) | 2010-02-26 |
| TW200602040A (en) | 2006-01-16 |
| DK1734959T3 (da) | 2010-03-08 |
| IL178168A0 (en) | 2006-12-31 |
| DE602005017373D1 (de) | 2009-12-10 |
| US20070129403A1 (en) | 2007-06-07 |
| AU2005231446A1 (en) | 2005-10-20 |
| CN1946399A (zh) | 2007-04-11 |
| BRPI0509512A (pt) | 2007-09-11 |
| EP1734959B1 (en) | 2009-10-28 |
| GT200500063A (es) | 2005-10-14 |
| PT1734959E (pt) | 2009-12-24 |
| CL2009001605A1 (es) | 2009-11-27 |
| ES2334241T3 (es) | 2010-03-08 |
| PA8628601A1 (es) | 2006-05-16 |
| JP2007531730A (ja) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2006002069A (es) | Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación | |
| UY28150A1 (es) | Agentes terapeuticos | |
| PE20060680A1 (es) | Compuestos de morfolina sustituida como inhibidores de la recaptacion de norepinefrina | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| PA8620501A1 (es) | Compuestos utiles en terapia | |
| AR060590A1 (es) | Compuestos imidazo | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| UY27740A1 (es) | Nuevos compuestos | |
| PE20040165A1 (es) | Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular | |
| UY29246A1 (es) | Nuevos compuestos | |
| AR071609A1 (es) | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| CO5011115A1 (es) | Compuestos y metodos quimioquina | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| AR036075A1 (es) | Compuestos derivados de pirimidina,triazina,y,pirazina,su uso, un procedimiento para su preparacion y medicamentos que los comprenden | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| PE20090110A1 (es) | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| PA8532001A1 (es) | Bifenilcarboxamidas utiles como agentes reductores de lipidos | |
| CL2007000773A1 (es) | Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd. | |
| PE20060734A1 (es) | Derivado de pirrol sustituido como antagonistas del receptor de androgenos | |
| NI200900073A (es) | Compuestos de carbamato para su uso en el tratamiento de la depresión. |